Treeline Biosciences announced a $200 million series A extension, totaling $1.1 billion raised to date, alongside unveiling its first three clinical-stage oncology candidates. The company’s pipeline includes a protein degrader targeting BCL6 in lymphoma, a broad KRAS mutation-targeting small molecule for solid tumors, and an EZH2 inhibitor in T-cell lymphoma. Treeline aims to support multiple programs with complementary timelines and patient populations, leveraging its substantial capital for long-term development.